Tramadol - Aytu BioScience

Drug Profile

Tramadol - Aytu BioScience

Alternative Names: BIO-301; DMI-7958; LI-301; LIF-301; Zertane

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Enhance Lifesciences
  • Developer Aytu BioScience
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Premature ejaculation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Premature-ejaculation in USA (PO, Tablet)
  • 15 Mar 2016 Biomarkers information updated
  • 19 Nov 2015 Aytu BioScience receives US FDA approval to initiate phase III studies in Premature ejaculation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top